Pulmonary Hypertension Due to Interstitial Lung Disease (PH-ILD): Optimizing Screening Strategies for Accurate Diagnosis and Timely Intervention
This activity is supported by an educational grant from United Therapeutics, a public benefit company.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from United Therapeutics, a public benefit company.
Activity Description
Pulmonary hypertension (PH) frequently complicates the course for patients with interstitial lung disease (ILD) and it is associated with adverse consequences such as increased oxygen needs, reduced functional ability, and increased mortality. Identification of PH-ILD can be challenging due to the potential overlap in presentation of PH attributed to other causes, as well as the similarity between the signs and symptoms of worsening ILD and PH-ILD. Optimal management of PH-ILD relies on routine screening, timely diagnosis, and awareness of evidence to support new therapeutic options. In this program, faculty will review key disease characteristics and outline evidence-based strategies for screening, identification, and treatment of PH-ILD. Interactive Rapid-Fire Roundtable discussions and case presentations will be included to highlight best practices and address common challenges with PH-ILD detection and management.
Target Audience
The intended audience for this activity is pulmonologists, nurse practitioners, and other healthcare professionals involved in the management of patients with PH-ILD.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Discuss the prevalence, burden, symptoms, latest knowledge regarding the disease state, and updated definition of pulmonary hypertension due to PH-ILD.
- Utilize screening strategies and diagnostic modalities to identify patients with PH-ILD including factors to guide decision-making regarding “when” to screen patients.
- Apply the latest clinical evidence regarding safety and efficacy of treatments for PH-ILD including the most recent findings from key clinical trials.
Activity Chair
Steven D. Nathan, MD, FCCP
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, VA
Faculty
Jean M. Elwing, MD, FACP, FCCP
Professor of Medicine
Director, Pulmonary Hypertension Program
Pulmonary Hypertension Association Certified Center (PHCCC)
Pulmonary, Critical Care and Sleep Medicine
University of Cincinnati
Cincinnati, OH
Oksana A. Shlobin, MD, FCCP
Medical Director, Pulmonary Hypertension Program
Director of Education, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Associate Professor of Clinical Education
University of Virginia School of Medicine
Fairfax, VA
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, December 31, 2023, to December 30, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Jean M. Elwing, MD, FACP, FCCP
Consultant: Altavant, Bayer, Insmed, Janssen/Actelion, Liquidia, United Therapeutics
Speaker Contracted by Ineligible Company: United Therapeutics
Independent Research Contractor: Actelion/Janssen, Altavant, Bayer, Liquidia, Pharmosa, United Therapeutics
Steven D. Nathan, MD, FCCP
Advisor: Bellerophon, Boehringer Ingelheim, Third Pole, United Therapeutics
Consultant: Avalyn, Bellerophon, Boehringer Ingelheim, Roche, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim, United Therapeutics
Oksana A. Shlobin, MD, FCCP
Advisor: Bayer, Janssen, United Therapeutics
Consultant: Aerami, Aerovate, Enzyvant, Merck, United Therapeutics
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this lecture is available upon request. Requests should include the activity title and emailed to CME@VindicoCME.com. Requests will be honored within 3 to 5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com